All patients in pembrolizumab trial were found to be cancer-free after combination of drug and surgery.
Category: biotech/medical – Page 355
Researchers based at the Dept of Biology and School of Physics, Engineering and Technology have developed a remarkable new technology which is able to study single biological molecules using intrinsic twist properties to bring about essential functions in cells.
“Nano twists” that drive life
There are myriad so-called “chiral” molecules in biology, which have a fascinating property of not appearing to have the same structure were you to look at their image in a mirror — one of the best known examples being DNA, the “molecule of life”, whose chirality comes from its amazing double helix structure. This chirality, which looks in the case of extended DNA molecules like “nano twists”, results in a property which physicists describe as “symmetry breaking” which in turn can drive molecules into a range of different states. With input from sources of energy, these molecules can then jump between different states as part of their normal function, and it is this state jumping which essentially drives all processes in living cells — so chirality is an enormously fundamental feature which in effect effect steers key cellular processes.
Though one in two people will develop some form of cancer in their lifetime, there’s still much we don’t know about this disease. But thanks to continued research efforts, we keep learning more about the biology of cancer. One of these recent discoveries could even transform our understanding of how cancers develop.
But before we talk about the new discovery, let’s first discuss the classical theory that attempts to explain why normal cells become cancer cells. This theory posits that DNA mutations are the primary cause of cancers.
It’s well known that ageing, as well as some lifestyle and environmental factors (such as smoking and UV radiation) cause random DNA mutations (also known as genetic alterations) in our cells. Most genetic alterations trigger cell death or have no consequence.
Move over, graphene. There’s a new, improved two-dimensional material in the lab. Borophene, the atomically thin version of boron first synthesized in 2015, is more conductive, thinner, lighter, stronger, and more flexible than graphene, the 2D version of carbon. Now, researchers at Penn State have made the material potentially more useful by imparting chirality — or handedness — on it, which could make for advanced sensors and implantable medical devices. The chirality, induced via a method never before used on borophene, enables the material to interact in unique ways with different biological units such as cells and protein precursors.
The team, led by Dipanjan Pan, Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine and professor of materials science and engineering and of nuclear engineering, published their work — the first of its kind, they said — in ACS Nano.
“Borophene is a very interesting material, as it resembles carbon very closely including its atomic weight and electron structure but with more remarkable properties. Researchers are only starting to explore its applications,” Pan said. “To the best of our knowledge, this is the first study to understand the biological interactions of borophene and the first report of imparting chirality on borophene structures.”
With over 37,000 views, this special issue discusses the relationship between phytochemicals and chronic disease prevention, aiming to promote the development of this field.
The special issue focuses on phytochemicals’ isolation, identification, structure–activity relationships, bioactivities, and…
This Special Issue, entitled Phytochemicals and Prevention of Chronic Diseases, features a series of high-quality research articles that explore the isolation, identification, and bioactivities of phytochemicals, as well as the underlying molecular mechanisms implicated in chronic diseases via antioxidation, neuroprotection, and the modulation of the gut microbiota.
Advanced glycation end products (AGEs) accumulate in the brain, leading to neurodegenerative conditions such as Alzheimer’s disease (AD). The pathophysiology of AD is influenced by receptors for AGEs and toll-like receptor 4 (TLR4). Protein glycation results in irreversible AGEs through a complicated series of reactions involving the formation of Schiff’s base, the Amadori reaction, followed by the Maillard reaction, which causes abnormal brain glucose metabolism, oxidative stress, malfunctioning mitochondria, plaque deposition, and neuronal death. Amyloid plaque and other stimuli activate macrophages, which are crucial immune cells in AD development, triggering the production of inflammatory molecules and contributing to the disease’s pathogenesis. The risk of AD is doubled by risk factors for atherosclerosis, dementia, advanced age, and type 2 diabetic mellitus (DM). As individuals age, the prevalence of neurological illnesses such as AD increases due to a decrease in glyoxalase levels and an increase in AGE accumulation. Insulin’s role in proteostasis influences hallmarks of AD-like tau phosphorylation and amyloid β peptide clearance, affecting lipid metabolism, inflammation, vasoreactivity, and vascular function. The high-mobility group box 1 (HMGB1) protein, a key initiator and activator of a neuroinflammatory response, has been linked to the development of neurodegenerative diseases such as AD. The TLR4 inhibitor was found to improve memory and learning impairment and decrease Aβ build-up. Therapeutic research into anti-glycation agents, receptor for advanced glycation end products (RAGE) inhibitors, and AGE breakers offers hope for intervention strategies. Dietary and lifestyle modifications can also slow AD progression. Newer therapeutic approaches targeting AGE-related pathways are needed.
Biomarkers are small molecules of interest to researchers, because they can indicate underlying diseases, often even before symptoms even appear. However, detecting these markers can be challenging as they are often present in very low quantities, especially in the early stages of a disease. Traditional detection methods, while effective, usually require expensive components like prisms, metal films, or optical objectives.
In a recent paper published in Applied Physics Letters, researchers at the University of Illinois Urbana-Champaign have unveiled a novel approach to detecting low concentrations of biomarkers that paves the way for biodetection technology that is simple to use, highly sensitive, and surprisingly affordable.
“The goal of this technology is early diagnostics, to be able to detect molecules associated with diseases at very low concentrations, sometimes a few molecules per millions, very early on,” said Seemesh Bhaskar, a postdoctoral researcher in Brian Cunningham’s lab and first author on the study. “Looking for very small concentrations of micro-RNA, circulating tumor DNA, and exosomes, for example, can help determine whether a patient will develop cancer one or two years down the line.”
Researchers at Cambridge have shown that the Third Thumb, a robotic prosthetic, can be quickly mastered by the public, enhancing manual dexterity. The study stresses the importance of inclusive design to ensure technologies benefit everyone, with significant findings on performance across different demographics.
Cambridge researchers demonstrated that people can rapidly learn to control a prosthetic extra thumb, known as a “third thumb,” and use it effectively to grasp and handle objects.
The team tested the robotic device on a diverse range of participants, which they say is essential for ensuring new technologies are inclusive and can work for everyone.
Cesarean section or C-section is a surgical procedure that delivers a baby through an abdominal incision. It is commonly used when the physicians believe it is a safer route for the parent, baby, or both. Cesarean section has appeared throughout history including Ancient Greece, India, Egypt, and Rome. There are even passages on cesarean section in different religious texts. It is believed that the name was attributed to the way Juluis Caesar was born. However, in Ancient Rome a cesarean section was only performed if at the time of birth, the mother was fatally ill and could not deliver naturally. It has been recorded that Julius Caesar’s mother was present during his life, therefore, historians believe he was not delivered through a cesarean section. Medical historians now believe the term originated from a decree in which Julius Caesar ordered women fated by birth to have a cesarean section which in Latin is “Caesones”. To this day, it is still incompletely understood where the name originated.
Cesarean sections are now routinely performed, and the procedure is well established. Interestingly, long-term effects of cesarean sections are not well known. Previously physicians noted no difference in health outcomes between children born through vaginal birth or cesarean section. Recently, however, a research group at the University of Cambridge found that a single dose of the measles vaccine is 2.6 times more likely to not be effective in children born through cesarean section. Unfortunately, a lack of vaccine efficacy leads to weakened immunity due to an inadequate number of antibodies produced to fight infection. While the first vaccination produced little efficacy, researchers demonstrated that a second measles vaccine was comparable to vaginally born children. More specifically, the vaccine was effective and produced the necessary antibodies to fight infection.
The recent paper published in Nature Microbiology by Dr. Henrik Salje, concluded the long-term effects of cesarean section delivery. Researchers suggest an increased risk of measles outbreak among children that were born through cesarean section and had only one measles vaccination. Salje and others explain that lack of vaccine efficacy is linked to the infants’ gut microbiome. It is well established that children receive great exposure to healthy microbes through vaginal birth, which boosts their immune systems. By avoiding microbe exposure through cesarean section, the infant loses critical immune protection.
Maj. Gen. Dr. Paul Friedrichs, MD is the Inaugural Director of the Office of Pandemic Preparedness and Response Policy, at the White House (OPPR — https://www.whitehouse.gov/oppr/), a permanent executive office aimed at leading, coordinating, and implementing actions to prepare for and respond to pathogens that could lead to a pandemic or significant public health-related disruptions in the U.S., and principal advisor on pandemic preparedness and response, appointed by President Biden.
Dr. Friedrichs was previously the Joint Staff Surgeon at the Pentagon where he provided medical advice to the Chairman of the Joint Chiefs of Staff, the Joint Staff and the Combatant Commanders, coordinating all issues related to health services, including operational medicine, force health protection and readiness among the combatant commands, the Office of the Secretary of Defense and the services. He also led the development and publication of the initial Joint Medical Estimate and served as medical advisor to the Department of Defense COVID-19 Task Force.
Dr. Friedrichs received his commission through the Reserve Officer Training Corps and his Doctor of Medicine (M.D.) from the Uniformed Services University. He has commanded at the squadron and group level, served as an Assistant Professor of Surgery and led joint and interagency teams which earned numerous awards, including “Best Air Force Hospital.” As Chair of the Military Health System’s Joint Task Force on High Reliability Organizations, he oversaw developing a roadmap to continuously improve military health care. As the Command Surgeon for Pacific Air Forces, U.S. Transportation Command and Air Combat Command, the general and his teams identified gaps, developed mitigation plans and enhanced readiness for future conflicts and contingencies.